GC
ARGS

Guggenheim Capital’s Argos Therapeutics, Inc. ARGS Stock Holding History

Guggenheim Capital’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,244
Closed -$4K – 2855
2017
Q4 		$4K Sell
1,244
-155
-11% -$520 ﹤0.01% 2704
2017
Q3 		$5K Buy
+1,399
New +$6.71K ﹤0.01% 2797

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Guggenheim Capital's ARGS Position: Q1 2018 in Review

Guggenheim Capital sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 1,244 shares — an estimated $4K sold.

Guggenheim Capital first reported a position in ARGS in Q3 2017 and held it in 2 quarters. The position peaked at $5K in Q3 2017. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

  • Guggenheim Capital reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Guggenheim Capital sold 1,244 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $4K.
  • Guggenheim Capital first reported a position in Argos Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Guggenheim Capital's Argos Therapeutics, Inc. position peaked at $5K in Q3 2017.
  • 16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Guggenheim Capital's 13F filing for Q1 2018, filed 15 May 2018.